Low frequency of COVID-19 in inflammatory bowel diseases.
作者信息
Marafini Irene, Salvatori Silvia, Sena Giorgia, Calabrese Emma, Biancone Livia, Monteleone Giovanni
机构信息
Department of Systems Medicine, University of Rome "TOR VERGATA", Rome, Italy; IBD group of Tor Vergata University Hospital, Rome, Italy.
Department of Systems Medicine, University of Rome "TOR VERGATA", Rome, Italy; IBD group of Tor Vergata University Hospital, Rome, Italy.
出版信息
Dig Liver Dis. 2020 Nov;52(11):1234-1235. doi: 10.1016/j.dld.2020.06.007. Epub 2020 Jun 13.
Abstract
摘要
相似文献
1
Low frequency of COVID-19 in inflammatory bowel diseases.炎症性肠病中新冠病毒病的低发病率
Dig Liver Dis. 2020 Nov;52(11):1234-1235. doi: 10.1016/j.dld.2020.06.007. Epub 2020 Jun 13.
2
The Incidence and Outcomes of COVID-19 in IBD Patients: A Rapid Review and Meta-analysis.炎症性肠病患者中新型冠状病毒肺炎的发病率及转归：一项快速综述与荟萃分析
Inflamm Bowel Dis. 2020 Sep 18;26(10):e132-e133. doi: 10.1093/ibd/izaa170.
3
Fogging IBD Management: An Unusual Case of IBD Flare-up During the COVID-19 Outbreak.雾化吸入在炎症性肠病管理中的应用：新冠疫情期间炎症性肠病发作的一个罕见病例
Inflamm Bowel Dis. 2020 Sep 18;26(10):e128-e129. doi: 10.1093/ibd/izaa184.
4
Risk of Severe Coronavirus Disease 2019 in Patients With Inflammatory Bowel Disease in the United States: A Multicenter Research Network Study.美国炎症性肠病患者发生重症2019冠状病毒病的风险：一项多中心研究网络研究
Gastroenterology. 2020 Oct;159(4):1575-1578.e4. doi: 10.1053/j.gastro.2020.06.003. Epub 2020 Jun 6.
5
Management of IBD Patients Who Are Unwilling or Unable to Receive Infusion Therapy During the COVID-19 Pandemic.2019冠状病毒病大流行期间不愿或无法接受输液治疗的炎症性肠病患者的管理
Inflamm Bowel Dis. 2020 Oct 23;26(11):e137. doi: 10.1093/ibd/izaa207.
6
Establishing Safe Out-of-Hospital Infusion Centers May Improve the Quality of Care in Patients With IBD During the COVID-19 Pandemic.建立安全的院外输液中心可能会改善新冠疫情期间炎症性肠病患者的护理质量。
Inflamm Bowel Dis. 2020 Oct 23;26(11):e140. doi: 10.1093/ibd/izaa246.
7
Clinical and Psychological Issues in Children with Inflammatory Bowel Disease During COVID-19 Pandemic.新冠疫情期间炎症性肠病患儿的临床与心理问题
Inflamm Bowel Dis. 2020 Aug 20;26(9):e95-e96. doi: 10.1093/ibd/izaa136.
8
Biologic Therapies May Reduce the Risk of COVID-19 in Patients With Inflammatory Bowel Disease.生物疗法可能降低炎症性肠病患者感染 COVID-19 的风险。
Inflamm Bowel Dis. 2020 Sep 18;26(10):e107-e109. doi: 10.1093/ibd/izaa242.
9
Critical importance of early introduction of prevention measures for SARS-CoV-2 infection in endoscopy units.在内镜检查科室尽早引入严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染预防措施的至关重要性。
Gastrointest Endosc. 2020 Oct;92(4):936-937. doi: 10.1016/j.gie.2020.06.023. Epub 2020 Jun 15.
10
COVID-19 vaccinations in patients with inflammatory bowel disease.炎症性肠病患者的新冠病毒疫苗接种
Lancet Gastroenterol Hepatol. 2020 Nov;5(11):965-966. doi: 10.1016/S2468-1253(20)30295-8. Epub 2020 Sep 21.
引用本文的文献
1
Impact of the COVID-19 Pandemic on the Lifestyle and Psychosocial Behavior of Patients with Inflammatory Bowel Diseases: A Narrative Review.2019年冠状病毒病大流行对炎症性肠病患者生活方式和心理社会行为的影响：一项叙述性综述
Healthcare (Basel). 2023 Sep 28;11(19):2642. doi: 10.3390/healthcare11192642.
2
Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis.炎症性肠病与 COVID-19 结局：荟萃分析。
Sci Rep. 2022 Dec 9;12(1):21333. doi: 10.1038/s41598-022-25429-2.
3
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.临床实践新进展：COVID-19 大流行期间炎症性肠病的管理。
Gut. 2022 Jul;71(7):1426-1439. doi: 10.1136/gutjnl-2021-326784. Epub 2022 Apr 27.
4
Corticosteroid and Biologic Use Not Associated With Adverse Outcomes for Inflammatory Bowel Disease Patients Hospitalized With COVID-19.对于因COVID-19住院的炎症性肠病患者，使用皮质类固醇和生物制剂与不良结局无关。
Gastroenterology Res. 2021 Dec;14(6):324-333. doi: 10.14740/gr1447. Epub 2021 Dec 21.
5
Long COVID in Inflammatory Bowel Diseases.炎症性肠病中的新冠长期症状
J Clin Med. 2021 Nov 26;10(23):5575. doi: 10.3390/jcm10235575.
6
Risk, Course, and Effect of SARS-CoV-2 Infection in Children and Adults with Chronic Inflammatory Bowel Diseases.患有慢性炎症性肠病的儿童和成人感染新型冠状病毒的风险、病程及影响
Children (Basel). 2021 Aug 30;8(9):753. doi: 10.3390/children8090753.
7
Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axis.SARS-CoV-2 对肠-脑-肺轴失调的治疗意义。
World J Gastroenterol. 2021 Aug 7;27(29):4763-4783. doi: 10.3748/wjg.v27.i29.4763.
8
Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta-analysis.炎症性肠病患者感染冠状病毒病的风险和结局：系统评价和荟萃分析。
United European Gastroenterol J. 2021 Mar;9(2):159-176. doi: 10.1177/2050640620972602. Epub 2021 Mar 23.
9
COVID-19 and immune-mediated inflammatory diseases: Why don't our patients get worse?2019冠状病毒病与免疫介导的炎症性疾病：为何我们的患者病情没有恶化？
Autoimmun Rev. 2020 Dec;19(12):102683. doi: 10.1016/j.autrev.2020.102683. Epub 2020 Oct 27.
10
Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock.对患有 2019 年冠状病毒病的炎症性肠病患者的系统评价：是时候进行总结了。
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2689-2700. doi: 10.1016/j.cgh.2020.08.003. Epub 2020 Aug 7.
Zotero 插件